{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:51:49Z","timestamp":1786971109010,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12032-020-01423-4","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T09:02:58Z","timestamp":1602925378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4082-6857","authenticated-orcid":false,"given":"Miyuki","family":"Okura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"issue":"20","key":"1423_CR1","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059\u201368.","journal-title":"Blood"},{"issue":"4","key":"1423_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","volume":"121","author":"P Lin","year":"2004","unstructured":"Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"5\u20136","key":"1423_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3109\/10428199609052420","volume":"20","author":"U Kaiser","year":"1996","unstructured":"Kaiser U, Auerbach B, Oldenburg M. The neural cell adhesion molecule NCAM in multiple myeloma. Leuk Lymphoma. 1996;20(5\u20136):389\u201395.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1423_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omede P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE. Report of the European Myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431\u20138.","journal-title":"Haematologica"},{"issue":"1","key":"1423_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","volume":"97","author":"AC Rawstron","year":"1997","unstructured":"Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97(1):46\u201355.","journal-title":"Br J Haematol"},{"issue":"4803","key":"1423_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1126\/science.3576199","volume":"236","author":"BA Cunningham","year":"1987","unstructured":"Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science. 1987;236(4803):799\u2013806.","journal-title":"Science"},{"issue":"4","key":"1423_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1046\/j.1365-2141.2002.03513.x","volume":"117","author":"N Sahara","year":"2002","unstructured":"Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, Ohnishi K, Ohno R. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117(4):882\u20135.","journal-title":"Br J Haematol"},{"issue":"1","key":"1423_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000490231","volume":"140","author":"K Miyazaki","year":"2018","unstructured":"Miyazaki K, Suzuki K. CD56 for Multiple Myeloma: Lack of CD56 May Be Associated with Worse Prognosis. Acta Haematol. 2018;140(1):40\u20131.","journal-title":"Acta Haematol"},{"issue":"4","key":"1423_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000489483","volume":"139","author":"M Skerget","year":"2018","unstructured":"Skerget M, Skopec B, Zadnik V, Zontar D, Podgornik H, Rebersek K, Furlan T, Cernelc P. CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction. Acta Haematol. 2018;139(4):228\u201334.","journal-title":"Acta Haematol"},{"issue":"4","key":"1423_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0925-5710(95)00363-W","volume":"61","author":"MM Kawano","year":"1995","unstructured":"Kawano MM, Mihara K, Tsujimoto T, Huang N, Kuramoto A. A new phenotypic classification of bone marrow plasmacytosis. Int J Hematol. 1995;61(4):179\u201388.","journal-title":"Int J Hematol"},{"issue":"10","key":"1423_CR11","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","volume":"81","author":"H Harada","year":"1993","unstructured":"Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81(10):2658\u201363.","journal-title":"Blood"},{"issue":"9","key":"1423_CR12","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1080\/10428194.2019.1574003","volume":"60","author":"S Oka","year":"2019","unstructured":"Oka S, Ono K, Nohgawa M. Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib. Leuk Lymphoma. 2019;60(9):2152\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1423_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1532\/IJH97.04189","volume":"81","author":"Y Kuroda","year":"2005","unstructured":"Kuroda Y, Sakai A, Okikawa Y, Munemasa S, Katayama Y, Hyodo H, Imagawa J, Takimoto Y, Okita H, Ohtaki M, Kimura A. The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents. Int J Hematol. 2005;81(4):335\u201341.","journal-title":"Int J Hematol"},{"issue":"8","key":"1423_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12032-016-0803-3","volume":"33","author":"N Iriyama","year":"2016","unstructured":"Iriyama N, Miura K, Hatta Y, Uchino Y, Kurita D, Takahashi H, Sakagami H, Sakagami M, Kobayashi Y, Nakagawa M, Ohtake S, Iizuka Y, Takei M. Plasma cell maturity as a predictor of prognosis in multiple myeloma. Med Oncol. 2016;33(8):87.","journal-title":"Med Oncol"},{"issue":"9","key":"1423_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12032-019-1298-5","volume":"36","author":"K Kurihara","year":"2019","unstructured":"Kurihara K, Iriyama N, Miura K, Uchino Y, Takahashi H, Nakagawa M, Iizuka K, Hamada T, Koike T, Hatta Y, Nakayama T, Takei M. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy. Med Oncol. 2019;36(9):75.","journal-title":"Med Oncol"},{"issue":"12","key":"1423_CR16","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u2013e548548.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1423_CR17","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1423_CR18","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1423_CR19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00277-014-2013-4","volume":"93","author":"N Iriyama","year":"2014","unstructured":"Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome. Ann Hematol. 2014;93(6):957\u201363.","journal-title":"Ann Hematol"},{"issue":"15","key":"1423_CR20","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"4848","key":"1423_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1126\/science.3281256","volume":"240","author":"U Rutishauser","year":"1988","unstructured":"Rutishauser U, Acheson A, Hall AK, Mann DM, Sunshine J. The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science. 1988;240(4848):53\u20137.","journal-title":"Science"},{"issue":"4","key":"1423_CR22","first-page":"1071","volume":"24","author":"Q Qiu","year":"2016","unstructured":"Qiu Q, Zhu P, Wang MJ, Lu XZ, Dong YJ, Sun YH, Wang LH, Zhang Y, Bu DF, Wang WS, Liang ZY, Liu W, Qiu ZX, Ou JP, Cen XN. Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(4):1071\u20138.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"5","key":"1423_CR23","doi-asserted-by":"publisher","first-page":"e0196780","DOI":"10.1371\/journal.pone.0196780","volume":"13","author":"T Yoshida","year":"2018","unstructured":"Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. PLoS ONE. 2018;13(5):e0196780.","journal-title":"PLoS ONE"},{"issue":"1","key":"1423_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10428190500272549","volume":"47","author":"H Chang","year":"2006","unstructured":"Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47(1):43\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"6113","key":"1423_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/326607a0","volume":"326","author":"Y Takada","year":"1987","unstructured":"Takada Y, Huang C, Hemler ME. Fibronectin receptor structures in the VLA family of heterodimers. Nature. 1987;326(6113):607\u20139.","journal-title":"Nature"},{"issue":"4","key":"1423_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2141.1995.tb05401.x","volume":"91","author":"MM Kawano","year":"1995","unstructured":"Kawano MM, Mahmoud MS, Huang N, Lisukov IA, Mihara K, Tsujimoto T, Kuramoto A. High proportions of VLA-5- immature myeloma cells correlated well with poor response to treatment in multiple myeloma. Br J Haematol. 1995;91(4):860\u20134.","journal-title":"Br J Haematol"},{"issue":"3","key":"1423_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289\u2013304.","journal-title":"Cancer Cell"},{"issue":"19","key":"1423_CR28","doi-asserted-by":"publisher","first-page":"28096","DOI":"10.18632\/oncotarget.8581","volume":"7","author":"M Jourdan","year":"2016","unstructured":"Jourdan M, Cren M, Schafer P, Robert N, Duperray C, Vincent L, Ceballos P, Cartron G, Rossi JF, Moreaux J, Chopra R, Klein B. Differential effects of lenalidomide during plasma cell differentiation. Oncotarget. 2016;7(19):28096\u2013111.","journal-title":"Oncotarget"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-020-01423-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-020-01423-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-020-01423-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T03:17:54Z","timestamp":1634440674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-020-01423-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1007\/s12032-020-01423-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"103"}}